The biological insight is the improved understanding of the role of both the tumor and non-tumor cell components of the tumor stroma and its importance in allowing in vivo-like responses to drugs. The innovation is the application of microfluidics to facilitate cis-coculture, or the culture of non-tumor microenvironmental cell components, without enrichment for a specific cell type, with tumor cells from the same patient, in comparison to monoculture (tumor cells alone). The integration of microfluidics and the tumor stroma, MicroC 3 , enables the rapid ex vivo analysis of therapeutic response of MM patient tumor cells to drug. Using statistical clustering methods, we show here that ex vivo responses of MM patient tumor cells to bortezomib strictly correlates with clinical response of the same patients to bortezomib-containing therapies.
Introduction
In vitro assays able to predict therapeutic response for specific 35 cancer patients would significantly advance efforts towards guiding treatment decisions and enabling individualized therapy. In the past, these assays have been termed Chemotherapy Sensitivity and Resistance Assays (CSRAs) [1] [2] [3] . Currently, there are no CSRAs approved for clinical use for any type of cancer [2] [3] [4] . 40 There are also technical limitations, such as too low of a tumor cell yield in some patients, inaccessibility of primary tumor cells for other assays, which limit the applicability of CSRAs to patients. Therefore, there is a need for the development of a new type of CSRAs suitable for clinical use, which also overcomes 45 some of the above technical difficulties. Multiple myeloma (MM) is the second most common hematological malignancy with a median survival of 5-7 years 5- 9 . With currently available combination therapies, initial responses to treatment can be as high as 90%. However, patients 50 inevitably relapse and become increasingly refractory to treatment, and the median survival following relapse can be as short as 6-9 months 10, 11 . Currently, there are several drug options and combinations to treat MM, including proteasome inhibitors, immunomodulatory compounds, steroids, and DNA damaging 55 agents 12, 13 . However, once patients relapse and/or become refractory, it becomes difficult to determine which therapies will be most effective, and quite often treatment is chosen largely on a trial and error basis. Another confounding factor for the choice of therapy is that even the most refractory patients will at times 60 respond to a different drug combination despite previous failed attempts. This results in patients being treated with potentially toxic and ineffective therapy until the "right" drugs are selected. Thus, there is an unmet medical need for novel predictive tools that could guide clinicians to make patient-specific treatment 65 decisions.
It is increasingly evident that the non-malignant cells in the tumor microenvironment also contribute key functions in the maintenance and progression of cancer cells as well as drug resistance 14 . Particularly in the case of MM, there are many cell 70 types in the bone marrow microenvironment, including bone marrow stromal cells (BMSCs), macrophages, osteoclasts, and other immune cells, which secrete a number of different cytokines and factors known to regulate different signaling pathways that may contribute to chemotherapy resistance in MM [14] [15] [16] [17] [18] . Moreover, cell-cell contacts can provide additional layer of 10 protection toward MM cells 19, 20 . In order to incorporate tumor microenvironment in in vitro assays, efforts are underway, including organoid assays and xenograft assays using primary patient samples, which may take such other non-tumor cell components into consideration for therapy-predictive assay 15 development [21] [22] [23] [24] .
Culture platforms utilizing microfluidics are gaining prominence because of their ability to measure cell behavior and function at single cell levels [25] [26] [27] [28] , allowing valuable information to be garnered from low starting material while at the same time 20 enabling more experimental conditions. Particularly with the advent of newer technologies, such as passive pumping and paper-based microfluidics, microfluidic devices have become more easily adapted for use by biologists, requiring only standard tools found in most biology labs 29, 30 . 31 was employed in this work to investigate its utility in the analysis of primary MM patient samples. In short, by leveraging pressure differences at differently sized inlet and outlet ports, this platform is operated by passive pumping 29 , requiring only a micropipet for operation. Suspension cells are seeded through the inlet port of the central well and are allowed to settle overnight ( Figure 1 ). Other cell types used for coculture studies are seeded through the inlet ports of the side chambers.
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This system incorporates the following features: 1) capacity to be performed for virtually all MM patients (i.e., 7500 cells per endpoint in the current study), 2) both tumor and non-tumor cells incorporated to mimic certain aspects of in vivo microenvironment, and 3) simple and quick to perform without 10 the need for extensive growth of the cells in vitro.
The entire assay requires 3 days to complete. On Day 1, after bone marrow aspiration, CD138 + tumor cells were sorted (within 24 hours of aspiration) and cultured in either mono-(MicroMC) or cis-coculture with the patients' own CD138 -non-tumor 15 mononuclear cell fractions (MicroC 3 ) (Figure 1 ). In the past, ciscoculture with a patient's own tumor and non-tumor cells, such as BMSCs, could only be accomplished from the individual bone marrow aspirate samples by cryopreservation of the MM tumor cells until BMSCs were established. This was necessary because 20 MM tumor cells are only viable for about 3 to 10 days ex vivo, while BMSCs take about 2 weeks to establish 34, 35 . However, we discovered that cryopreservation of MM tumor cells resulted in a great loss of viability of patient cells, with an average of ~25% of cells being viable after thaw (Table S1) 31 . Live and dead cells were counted using an ImageJbased in house software program (J'experiment) 31 . Live fractions for each dose were calculated and normalized to the 0 dose (40 hr, Day 3) in the absence of drug treatment ( Figure   10 indicated that the viability of MM cells at different time points was comparable among patients ( Figure 2B ) and to that of a MM cell line, RPMI8226 ( Figure 2C ). To maximize the yield of drug response trend of MM cells from individual patient samples, we chose to perform dose-response analysis instead of technical 15 replicates at an arbitrary dose. Some technical replicates were performed only when the MM cell yield was sufficient for such studies ( Figures S2 and S3 ). 
Distribution and statistical clustering analysis of ex vivo
The % fractions of surviving MM cells in response to in MicroMC and MicroC 3 for patient samples analyzed are shown in Figures 3A and B, The patient characteristics are presented in Table 1 . To understand the relationship between effective concentrations annels and those reported in patients 36, 37 , we incubated 100 nM bortezomib for different times and measured the ability of remaining bortezomib in the media to inhibit the proteasome activity present in RPMI8226 MM cells by performing the Proteasome-Glo Assay (see Materials and Methods section).
From these values, we 5 extrapolated the relative concentrations of bortezomib present in microchannels over time and found approximately 0 nM at 12 hrs and later. The calculated area under the curve (AUC) amount of bortezomib for the 100 nM dose incubated over 24 hours in microchannels was 112.92 ng*h/mL ( Figure S1 ). The plasma 10 concentration of bortezomib peaks between 50 to 200 nM and drops off sharply when administered intraveneously or a slightly slower following subcutaneously injection 36, 37 . Nevertheless, the AUC was reported to be comparable between the two administrative routes being ~70 to 150 ng*h/mL. Thus, our data 15 suggested that the addition of 100 nM bortezomib in microchannels exposed MM cells with AUC profiles approximating those seen in patient plasma.
Subsequently, the percent changes in live fraction of MM cells from the 0 nM to 100 nM dose of bortezomib in MicroMC and 20 
MicroC
3 for all patients were calculated. Figure S2 shows 3 , a bimodal distribution of the response data was favored by the AIC as well as the BIC over unimodal and trimodal distributions (Table S3 ). In contrast, 35 none of these distributions was favored by AIC or BIC for MicroMC responses.
As both the AIC and BIC values indicated that a bimodal distribution was favored for MicroC 3 , k-means and Gaussian mixture clustering methods were applied to segregate MicroC 3 ex 40 vivo responses. The k-means and Gaussian mixture clustering analyses segregated 17 ex vivo responses in MicroC 3 into two clusters: 1 -non-sensitive (10 cases), 2 -sensitive (7 cases) ( Table S3 ). The separation of the two resulting clusters (p < 10 -5 ) ( Figure 3C , right two plots) was further in line with the Otsu 45 threshold independently derived for the same data ( Figure S2 ).
Correlation of ex vivo MM cell drug responses to clinical responses of corresponding patients
The ex vivo responses within MicroMC and MicroC 3 were next 50 compared with the clinical responses of the same patients. The top half of Table 1 lists patients whose bone marrow biopsies were collected prior to bortezomib-containing therapy; while the bottom half lists patients whose bone marrow aspirates collected post bortezomib-containing therapy. According to IMWG 55 criteria, patients were deemed to be responsive if they had a partial response (PR) or greater and refractory or non-responsive if they had stable disease, progressive disease, relapsed and/or become refractory 38 60 determined by response to their next bortezomib-containing therapy. For patients whose samples were collected post therapy, their clinical responses were determined by current status at the time of biopsy. All samples were collected and analyzed ex vivo without the prior knowledge of patients' clinical history to 65 eliminate operator bias. The clinician determining responses was also blinded of the ex vivo response data.
Remarkably, the MicroC 3 clusters separated by k-means and Gaussian mixture clustering into non-sensitive and sensitive were correctly identified as either clinically non-responsive or 70 responsive, regardless of whether the aspirate was acquired prior to or post bortezomib-containing therapy ( Figure 3C , right plots, Table S3 ). In contrast, only 12/15 (7/8 non-sensitive and 5/7 sensitive) of MicroMC responses ( Figure S5) Figure S5 ) and this patient's clinical response was non-responsive. However, when included in the clustering 95 analyses, trimodal distributions were favored with the Pt 402's ex vivo response being classified as a third cluster (Table S4) . Thus, while his ex vivo response in MicroC 3 (but not in MicroMC) matched his clinical response, Pt 402 was removed as a statistical anomaly. Peculiarly, Pt 402 was the only patient with a t(14;16) 100 translocation affecting c-Maf oncogene with a very poor prognosis that occurs in ~5% of MM patients [39] [40] [41] .
MicroC 3 ex vivo responses and patient clinical responses to future bortezomib-containing therapy
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Pt's 317, 318, and 323 were newly diagnosed patients and their tumor cell responses were classified as sensitive to bortezomib in MicroC 3 assay (Figure 3 ). These patients then went on bortezomib-containing regimens without the clinician's prior knowledge of the ex vivo responses ( assay at biopsy was classified as sensitive ( Figure 3 ). This patient then went on a bortezomib-containing therapy and had a partial response. In contrast, Pt. 442 was a newly diagnosed patient whose tumor cells were classified as bortezomib non-sensitive in MicroC 3 assay (Figure 3 ). This patient then went on a bortezomib-containing regimen, again without the clinician's 5 prior knowledge of the ex vivo data, and did not respond clinically. Therefore, these patients' CD138
+ cell response to bortezomib in the MicroC 3 system correlated with the patients' future clinical response to bortezomib-containing therapy.
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Discussion
A predictive CSRA that enables stratification of patients prior to specific therapy would allow patients to avoid ineffective therapies as well as unnecessary cost associated with such therapies. In the present study, we have developed and tested 15 MicroC 3 , a microfluidics-based cis-coculture CSRA, which incorporates several new features into an ex vivo predictive assay platform while being accessible to researchers without the need for highly sophisticated technical capabilities. First, both tumor and non-tumor cells from the same patients are incorporated to 20 capture tumor and non-tumor cell heterogeneity in individual patient samples. Second, the MicroC 3 analyzes only thousands of CD138 + cells per condition, thereby making it applicable to virtually all MM patients. And finally, the MicroC 3 assay operation is simple and takes only three days from the sample 25 acquisition to the analysis of the cell responses, negating the need for extended culturing and passaging of the patient cells, which could alter their phenotypes. Significantly, MicroC 3 CSRA segregated ex vivo patient tumor cell responses to bortezomib into two clusters, which correctly identified patients' clinical 30 responses to bortezomib-containing therapies.
Our previous and others' studies suggested that both nontumor cells, such as BMSCs and macrophages, and MM cells from individual patients display considerable heterogeneity in signaling responses and functions 32, 16, 18, 15 . To incorporate both 35 tumor and non-tumor cell heterogeneity in the design of in vitro toxicity assay, we avoided artificial enrichment of a specific cell population, such as BMSCs or macrophages, and associated bias of functional contributions via soluble factors produced by them 15, 42 . Bortezomib can also exert effects on non-tumor cells 40 within the MM tumor microenvironment, in addition to direct effects on MM cells [14] [15] [16] 43, 44 . Thus, incorporation of total CD138 -cell population in MicroC 3 likely enabled ex vivo recapitulation of key aspects of tumor microenvironment 14, [45] [46] [47] [48] distinguishing it from traditional monoculture designs used in 45 previous CSRAs 1-3 . Another critical feature of MicroC 3 is the microscale analysis of patient MM cell toxicity. The low fluid volumes may concentrate important soluble factors produced by both the tumor and non-tumor companion cells which may otherwise be diluted 50 in conventional culture conditions (e.g., Transwell cultures). Other studies have also suggested that these and other inherent properties of microfluidic culture, including lack of convection and transport by diffusion, lead to an improved simulation of the tumor microenvironment 26, 49, 50 . Though the inclusion of the 55 tumor microenvironment components in microscale assays is becoming increasingly popular -and powerful -through the development of cells-, tissues-, and organs-on-chips [51] [52] [53] , as well as the patterning of different cell types and microfluidic Campenot chambers 51, 52, 54 20, 67 , and modifications to accommodate such a mechanism may lead to an improved CSRA platform. To accommodate this change in the future, one could simply add matrix or tumor and non-tumor cells together in the central well. Fourth, an additional study could test if MicroC 3 is also amenable 105 to analysis of extramedullary myeloma that is also infiltrated by non-tumor cells, such as macrophages 16 , using patients' blood samples. Fifth, the MicroC 3 assay should also be tested with other hematological malignancies 31 , particularly those that support sampling of both tumor cell and non-tumor cells. Finally,
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MicroC 3 can be configured into a high throughput format with alternative device materials (such as polystyrene), robotic automation to minimize operator bias, and improved accuracy of sample handling and data acquisition. While other efforts are also underway by employing mono-and coculture systems (e.g., 115 ex vivo 3-D RCCS TM bioreactor) 21 , in vivo xenograft models (e.g., humanized mouse models) 22, [68] [69] [70] , and patient-derived xenograft (PDX) models 71 to capture aspects of the patients' tumor microenvironment, further improvements in the MicroC 3 platform could provide a readily accessible, automated, and high-5 throughput CSRA for hematological malignancies.
Materials and Methods
Microchannel fabrication and preparation
Single-use devices comprised of 12 or 24 cell culture chambers were fabricated using soft lithography using two master molds 10 established previously 72, 73 . Polydimethylsiloxane (PDMS) was mixed at a 10:1 base:curing agent ratio, poured on the master molds, and cured at 80°C for 4 hrs. Two separate PDMS layers were made, one for the channel layers containing the central well, side chambers, diffusion ports, and inlet and outlet channels, and 15 one for the access port layer. The two PDMS layers were then soxhlet extracted and plasma treated to bond to a glass slide. The final device was then baked at 120°C for 15 min to increase bond strength and release any bubbles.
Before cell culture, the chambers on the device were filled first 20 with 70% ethanol as a wetting agent as well as a disinfectant. The ethanol was rinsed with 3 volume replacements (VRs) of 1X phosphate-buffered saline (PBS). The 1X PBS was then replaced with 3 VRs of the appropriate cell culture medium. The final such prepared device could be stored up to 3 weeks in a 37°C 25 incubator when encased with appropriate humidifying and sterile conditions. When stored longer than 24 hours, the media was replaced with 1 VR of fresh media prior to cell seeding.
Cell line culture and preparation
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RPMI8226 (human MM cell line) was obtained from ATCC. RPMI8226 cells (1.0 to 1.5 x 10 5 cells/mL seeding density) were routinely cultured at 37°C with 5% CO 2 in high-glucose Dulbecco's modified eagle's medium (DMEM) containing 10% fetal bovine serum (FBS), 100U/mL penicillin, 100g/mL Group (IMWG) criteria 38 . 'Sensitive or Responsive' is defined as patient achieving at least a partial remission/response. 'Relapsed' is defined as patient having > 0.5g/dl increase in monoclonal protein or >200mg in 24 hours in urine light chains after obtaining at least a partial remission. 'Refractory or Resistant' is 55 defined as patient having progressed on or within sixty days of treatment. Relapsed and/or refractory patients were defined as non-responsive patients for the purpose of this assay. The researcher assessing clinical statuses of the patients was blinded to assay results and separate from the staff performing the assay. 60 The ex vivo data and the clinical statuses were only compared after the assay was completed.
Aspirate volumes were doubled with Iscove's Modified Dulbecco's Medium (IMDM) + 100 units/mL heparin (SigmaAldrich). They were doubled again with IMDM + 10 units/mL 
Reagents
Bortezomib (PS-341 or Velcade) was obtained as a 2.6mM clinical saline solution from Millenium Pharmaceuticals and stored at -80°C in separate aliquots. The drug was thawed 5 minutes before each treatment, serially diluted to the desired 105 concentrations in media warmed to 37°C, and dispensed into microchambers in 3 sequential VRs followed by aspiration of the outlet port to reach desired final concentrations. LIVE/DEAD Viability/Cytotoxicity Assay Kit from Invitrogen was used to detect live and dead cells in microchambers. Both calcein AM 110 (green) and ethidium homodimer (red) were used at a working concentration of 4μM.
Proteasome Activity Assay
Chymotryptic proteasomal activity was measured using the Proteasome-Glo Assay (Promega, Inc). RPMI8226 MM cells (5,000 per well), were plated in a white-walled 384-well tissue culture dish, allowed to rest for a minimum of 3 hours, and 5 treated with increasing doses of bortezomib for 105 minutes before addition of the luminescent reagent as directed by the manufacturer in order to establish a standard curve of inhibition of the proteasome by differing concentrations of bortezomib. Luminescence was read on a Perkin-Elmer ENSPIRE plate 10 reader. Relative light units for the no drug control were designated 100% proteasome activity, and the ratio of relative light units for each dose of bortezomib over control was used to determine the percentage decrease in chymotryptic activity. In order to extrapolate the bortezomib concentration over time 15 within MicroC 3 channels, 100 nM bortezomib in media was added to MicroC 3 at different timepoints from 0 hr to 24 hrs. The media was then extracted after those timepoints and used to treat the RPMI8226 cells at a 10-fold dilution for 105 minutes. The same protocol as above was followed in order to determine 20 percent inhibition of the proteasome. This percent inhibition of the proteasome was used to extrapolate an approximate molar concentration of bortezomib. After conversion of the molar concentration of bortezomib to ng/mL, the approximate concentration of bortezomib within MicroC 3 over time was used 25 to calculate an AUC (ng x time in hrs/mL).
Immunofluorescence image analysis
Cells were stained with LIVE/DEAD for 10 min, and washed with one VR of fresh media. All fluorescent images were taken 30 with a Nikon Eclipse Ti inverted fluorescent microscope coupled to a Nikon DS-Qi1Mc CCD camera (Nikon Instruments Inc., Melville, NY, USA) at a magnification of 4x. Image analysis was performed in ImageJ with custom in-house algorithms and database management to count live and dead cells (J'experiment) 35 
.
Statistical Analysis
Monocultured live fraction responses to bortezomib were normalized to the monoculture 0 dose; cis-cocultured live fraction 40 responses to bortezomib were normalized to the coculture 0 dose. The changes in live fractions as a response to 30 nM and 100 nM doses of bortezomib were calculated. The mean, standard deviation, median, interquartile range (IQR), and Otsu threshold 74 were calculated for both monoculture and cis-coculture 45 responses in Matlab (MathWorks, Nattick, MA) and graphed using Origin (OriginLab, Northampton, MA).
Clustering analysis of ex vivo data
In order to automatically identify potential distinct 50 subpopulations in an unsupervised fashion and with high discriminative power, ex vivo data were separated using both kmeans clustering 75 and Gaussian mixture (GM) modeling 76 algorithms. We chose to compare both methods for robustness. In both methods, the data set is iteratively partitioned into k clusters 55 by minimizing the within-cluster variance while maximizing the between-cluster variance. Clustering of the ex vivo response data was carried out using the Statistics Toolbox of Matlab (MathWorks, Nattick, MA). The degree of dimensionality (i.e., the numbers of clusters) was determined by a) maximizing the 60 mean 
Conclusions
With a collaboration that crossed multiple disciplines, including biomedical engineering, cellular biology, medicine, and statistics, 85 we developed a microfluidic cis-coculture assay, MicroC 3 
